Company: INTS
Filing Date: 2025-06-12
Form Type: 424B5
Source: 0001628280-25-031040
Chunk: 15

Company: INTENSITY THERAPEUTICS, INC.
Filing Date: 2025-06-12
Form: 424B5
Chunk 15
---
 from their currently intended use. The failure by our management to apply these funds effectively could result in financial losses that could have a material adverse effect on our business, cause the price of our common stock to decline and delay the development of our drug candidates. Pending their use, we may invest the net proceeds from this offering in short-term, investment-grade, interest-bearing instruments, which may not yield a favorable return to our stockholders.

If you purchase securities in this offering, you will suffer immediate dilution of your investment.

We expect that the public offering price of our common stock in this offering will be higher than the net tangible book value per share of our common stock. Therefore, if you purchase shares of our common stock in this offering, you will pay a price per share that substantially exceeds our pro forma as adjusted net tangible book value per share after this offering. Based on the public offering price of $0.30 per share, our as pro forma as adjusted net tangible book value as of March 31, 2025 would have been $3.6 million, or $0.14 per share, resulting in an immediate increase in the pro forma net tangible book value per share of $0.02 to existing stockholders and an

<div align='center'>S-9</div>

immediate dilution of $0.16 in pro forma as adjusted net tangible book value per share to investors purchasing common stock in this offering, representing the difference between our pro forma as adjusted net tangible book value per share after giving effect to this offering. To the extent outstanding stock options or warrants are exercised, there will be further dilution to new investors. See “Dilution.”

You may experience future dilution as a result of future equity offerings.

In order to raise additional capital, we expect to offer additional shares of our common stock or other securities convertible into or exchangeable for our common stock in the future. We cannot assure you that we will be able to sell shares or other securities in any other offering at a price that is equal to or greater than the price per share paid by investors in this offering, and investors purchasing shares or other securities in the future could have rights superior to existing stockholders. The price at which we sell additional shares of our common stock or other securities convertible into or exchangeable for our common stock in future transactions may be higher or lower than the price per share in this offering.

Because there are no current plans to pay cash dividends on our common stock for the foreseeable future, you may not receive any return on